Pancreatic Cancer Research

ResearcherNational Hospital Organization Saga National HospitalActive in the last 2 years

Yasushi Ide

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-0164-0168; OpenAlex author ID A5063119641. Sources: OpenAlex.

Their work

Papers
18
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2021: 3 papers · 2022: 2 papers · 2023: 5 papers · 2024: 2 papers · 2025: 2 papers · 2026: 4 papers

Papers 18

  1. Chemotherapy-induced neutropenia predicts short-term outcome of patients with pancreatic cancer treated with nanoliposomal irinotecan, fluorouracil, and folini… Co-author DOI 10.1002/ijc.70072↗
  2. Predictors of prolonged progression-free survival in patients with unresectable or recurrent pancreatic cancer treated with nanoliposomal irinotecan with fluor… Co-author DOI 10.1177/17588359261442386↗
  3. Effect of biliary drainage and biliary tract infection in unresectable pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic ac… Co-author DOI 10.1186/s12885-026-16237-2↗
  4. Dynamic analysis of C-reactive protein/albumin ratio in pancreatic cancer Co-author DOI 10.21203/rs.3.rs-8417823/v1↗
  5. Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: a multicenter observational study (NA… Co-author DOI 10.1016/j.esmogo.2025.100150↗
  6. Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Cancer: Results of NAPOLEON-1 and 2 Studie… Co-author DOI 10.1159/000542137↗
  7. Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or ge… Co-author DOI 10.1038/s41598-024-55673-7↗
  8. Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/… Co-author DOI 10.1038/s41598-024-65689-8↗
  9. Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study. Co-author DOI 10.1007/s10147-023-02354-6↗
  10. C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-… Co-author DOI 10.1038/s41598-023-34962-7↗
  11. Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer. Co-author DOI 10.1038/s41598-023-46924-0↗
  12. Multicenter Retrospective Analysis of Original versus Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Results of the NAPOLEON Study. Co-author DOI 10.1159/000527176↗
  13. Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel. Co-author DOI 10.21873/anticanres.16335↗
  14. Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAP… Co-author DOI 10.1016/j.jgo.2021.06.011↗
  15. Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multi… Co-author DOI 10.1186/s12885-021-09139-y↗
  16. A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results fr… Co-author DOI 10.1007/s10147-021-01859-2↗
  17. Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study). Co-author DOI 10.1097/mpa.0000000000001859↗
  18. Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel Versus FOLFIRINOX for Recurrent Pancreatic Cancer After Resection. Co-author DOI 10.21873/anticanres.15145↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Junichi Nakazawa · 17 shared papers, 2021–2026 · strength 2.48
  2. Kenji Mitsugi · 17 shared papers, 2021–2026 · strength 2.48
  3. Shiho Arima · 17 shared papers, 2021–2026 · strength 2.48
  4. Futa Koga · 17 shared papers, 2021–2026 · strength 2.48
  5. Mototsugu Shimokawa · 17 shared papers, 2021–2026 · strength 2.48
  6. Taiga Otsuka · 17 shared papers, 2021–2026 · strength 2.48
  7. Tsuyoshi Shirakawa · 17 shared papers, 2021–2026 · strength 2.48
  8. Hiroki Taguchi · 17 shared papers, 2021–2026 · strength 2.48
  9. Norio Ureshino · 13 shared papers, 2021–2025 · strength 1.68
  10. Taro Shibuki · 13 shared papers, 2021–2025 · strength 1.68
  11. Masaru Fukahori · 13 shared papers, 2021–2025 · strength 1.68
  12. Azusa Komori · 13 shared papers, 2021–2025 · strength 1.68
  13. Yasunori Kawaguchi · 8 shared papers, 2021–2026 · strength 1.32
  14. Kazuo Nishikawa · 6 shared papers, 2024–2026 · strength 1.10
  15. Shuji Arita · 6 shared papers, 2024–2026 · strength 1.10
  16. Tomonori Araki · 3 shared papers, 2025–2026 · strength 0.56
  17. Yoshinobu Okabe · 4 shared papers, 2021–2024 · strength 0.52
  18. Keisuke Miwa · 3 shared papers, 2023–2025 · strength 0.44
  19. Akio Ido · 3 shared papers, 2021–2023 · strength 0.33
  20. Eishi Baba · 2 shared papers, 2023–2024 · strength 0.30
  21. Wataru Yoshioka · 1 shared paper, 2026 · strength 0.20
  22. Tomoyuki Ushijima · 1 shared paper, 2023 · strength 0.14
  23. Shinichi Hashimoto · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.